Source: International Congress 2015 – Pulmonary hypertension: new treatment insights
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Michael Halank (Dresden, Germany), Michael Halank, Marc Humbert, Miguel-Angel Gomez Sanchez, David Pittrow, Marius Hoeper, Ekkehard Grünig, H. Ardeschir Ghofrani, Hubert Wirtz, Hans Klose, Ralf Ewert, Tobias J. Lange, Jens Klotsche, Christian Meier, Monika Brunn, Gerald Simonneau. Riociguat for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Real-life data from the EXPERT registry. Eur Respir J 2015; 46: Suppl. 59, 4999

Member's Comments

No comment yet.

Related content which might interest you: Riociguat for the treatment of pulmonary hypertension: Safety data from the EXPERT registry Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016 Riociguat in pulmonary arterial hypertension: ERS/ESC risk assessment in PATENT Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016 Riociguat in chronic thromboembolic pulmonary hypertension (CTEPH): ERS/ESC risk assessment in CHEST Source: International Congress 2016 – Pulmonary hypertension and chronic thromboembolic pulmonary hypertension Year: 2016 Global fibrinolytic profile in patients with chronic thromboembolic pulmonary hypertension Source: International Congress 2015 – Pulmonary circulation: pulmonary embolism and chronic thromboembolic pulmonary hypertension Year: 2015 Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension Source: Eur Respir J, 53 (6) 1802004; 10.1183/13993003.02004-2018 Year: 2019 Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: pathophysiology Source: Eur Respir Rev 2009; 19: 59-63 Year: 2010 Acute haemodynamic effects of adaptive servoventilation therapy in patients with pulmonary arterial hypertension and patients with chronic thromboembolic pulmonary hypertension Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015 COVID-19 in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: a reference centre survey Source: ERJ Open Res, 6 (4) 00520-2020; 10.1183/23120541.00520-2020 Year: 2020 Real-life data on the medical therapy of pulmonary arterial and chronic thromboembolic pulmonary hypertension Source: International Congress 2017 – PAH and CTEPH Year: 2017 LATE-BREAKING ABSTRACT: Riociguat for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH): 2-year results from the CHEST-2 long-term extension Source: International Congress 2014 – New technologies and biomarkers in lung disease Year: 2014 Incidence and outcomes of haemoptysis in patients with operable and non-operable chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) Source: International Congress 2016 – Pulmonary hypertension and chronic thromboembolic pulmonary hypertension Year: 2016 Prevalence of relapses and chronic thromboembolic pulmonary hypertension (CTEPH) in patients with pulmonary embolism (PE) Source: International Congress 2016 – Pulmonary hypertension: exercise, haemodynamics, and physiology Year: 2016 Riociguat for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH): Final data from a phase II long-term extension (LTE) study Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots Year: 2015 ERS statement on chronic thromboembolic pulmonary hypertension Source: ERS webinar 2021: ERS statement on chronic thromboembolic pulmonary hypertension Year: 2021 Adherence to guidelines of anticoagulant prescription in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: an observational study Source: Virtual Congress 2020 – Chronic thromboembolic pulmonary hypertension Year: 2020 Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study Source: Eur Respir J 2010; 36: 792-799 Year: 2010 Surgical and post-operative treatment of chronic thromboembolic pulmonary hypertension Source: Eur Respir Rev 2009; 19: 64-67 Year: 2010 Chronic thromboembolic pulmonary hypertension: role of medical therapy Source: Eur Respir J 2013; 41: 985-990 Year: 2013 Effect of pulmonary-specific vasodilator therapy in patients with chronic obstructive pulmonary disease and pulmonary hypertension. A retrospective analysis Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Long-term safety of a new formulation of epoprostenol in pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment Year: 2013